Sundaram Multi Pap Ltd Share Price Today

Sundaram Multi Pap Ltd. Share Price

Overview

Sundaram Multi Pap Ltd. share price is currently ₹0.97, down by - ₹0.04 (3.96%) from its previous closing price of ₹1.01. The share price has declined -13.51% over the past month and declined -38.85% over the past year. The stock's 52-week low and high are ₹0.94 and ₹1.82, respectively. Sundaram Multi Pap Ltd. has a market capitalisation of ₹ 53.50 Cr. The share price was last updated on 23 Oct 2026, 01:43 PM IST.

Rahul Porwal

10 Oct • 2:53 PM · SEBI-Registered Analyst

Sundaram-Clayton (Sunclay) reported a consolidated net loss

SUNCLAY

Sundaram-Clayton (Sunclay) reported a consolidated net loss of ₹59 crore in Q1 FY27 (ended June 30, 2026), despite a 16% rise in revenue to ₹592 crore. Rising input costs, higher aluminium prices, and geopolitical uncertainties weighed heavily on margins. 📊 Key Financial Highlights Consolidated Net Loss: ₹59 crore (vs. ₹58 crore loss last year). Revenue Growth: ₹592 crore, up 16% YoY. Standalone Performance: Net profit of ₹17 crore, flat compared to last year. Operating Profit: Fell sharply to ₹11.9 crore from ₹39 crore in the previous quarter. 🚗 Industry & Market Context Indian Automobile Industry: Resilient demand supported by infrastructure-led investments. Commercial Vehicles (CV): Steady growth driven by construction and replacement demand. Passenger Vehicles (PV): Strong demand, especially SUVs and hybrids.

CA Barkha Kamra

8 Sep • 12:33 PM · SEBI-Registered Analyst

Sundaram Home Finance targets ₹1,300 crore AUM in Tamil Nadu

Sundaram Home Finance, part of the

SUNDARMFIN

, is targeting a significant expansion in its emerging business segment in Tamil Nadu, with plans to nearly double assets under management (AUM) to around ₹1,300 crore by the end of the current fiscal year. The company’s AUM in this segment stood at more than ₹650 crore in FY26, implying a potential increase of roughly 100% over the existing base. The expansion highlights the company’s growing focus on underserved and emerging customer segments across Tamil Nadu, where demand for housing finance and related credit remains strong. The strategy is expected to be supported by deeper penetration into smaller towns and developing markets, wider customer outreach and continued expansion of the company’s lending franchise. Growth in the emerging business segment can help Sundaram Home Finance diversify its portfolio while creating a larger base of retail borrowers. The targeted AUM milestone also underscores management’s confidence in the long-term credit demand from customers outside the traditional housing-finance markets. For the broader Sundaram Finance ecosystem, faster growth at Sundaram Home Finance could strengthen its presence in Tamil Nadu’s retail financial-services market. However, achieving the target will depend on maintaining asset quality, prudent underwriting and effective branch and customer expansion while scaling the loan book. Overall, the planned doubling of AUM represents an aggressive growth objective and signals strong confidence in the opportunity available in Tamil Nadu’s emerging housing-finance segment.

Pavan Rawat

5 Aug • 9:26 AM · SEBI-Registered Analyst

POONAWALLA

The PFL Employee Welfare Trust sold shares worth ₹223 crore in Poonawalla Fincorp, while Goldman Sachs picked up a stake worth ₹100 crore in Sudeep Pharma through open market transactions on August 4. According to block deal data, the PFL Employee Welfare Trust offloaded 47.08 lakh shares, representing a 0.53% stake in Poonawalla Fincorp, for ₹222.96 crore. The trust, which manages company shares for employee welfare, sold the shares at ₹473.50 apiece. The buyers included Sundaram Mutual Fund, HDFC Life Insurance Company, Helios Mutual Fund, and Morgan Stanley Asia Singapore Pte. Following the transaction, Poonawalla Fincorp shares ended 0.48% lower at ₹469.65 on the National Stock Exchange. In a separate transaction, Goldman Sachs acquired 11.76 lakh shares of Sudeep Pharma for around ₹100 crore at ₹850 per share. The shares were sold by Nuvama Crossover Opportunities Fund – Series III and Series IIIA, which offloaded 6.14 lakh and 5.62 lakh shares, respectively. As of June 2026, the two funds held 2.95% and 2.57% stakes in the company. Rajgor Castor Derivatives also witnessed block deal activity. Unicorn Fund sold 8.97 lakh shares, equivalent to a 3.75% stake, for ₹2.95 crore at ₹32.94 per share. As of March 2026, the fund owned a 5.76% stake, or 13.77 lakh shares, in the company. Meanwhile, Alchemy Capital Management's Alchemy Long Term Ventures Fund Series 3 acquired 2.06 lakh shares of Aimtron for ₹30.48 crore at ₹1,480 per share. On the other side of the transaction, promoter Mukesh Jeram Vasani sold 2.10 lakh shares at ₹1,480.09 apiece, amounting to ₹31.08 crore.

SASI KUMAR SEBI RA

3 Aug • 7:45 AM · SEBI-Registered Analyst

Today's Q1 FY27

Good morning everyone! 🙏 Stocks areannouncing their Q1 FY27 results today 👇 ✧ DLF ✧ UPL ✧ Torrent Power ✧ CAMS (Computer Age Management Services) ✧ IREDA ✧ Jindal Stainless ✧ KEI Industries ✧ Sundaram Finance ✧ Escorts Kubota ✧ Ather Energy ✧ Nazara Technologies ✧ DOMS Industries ✧ Kansai Nerolac Paints ✧ KIMS (Krishna Institute of Medical Sciences) ✧ Great Eastern Shipping DLF, UPL, IREDA, CAMS and Torrent Power are likely to be among the most watched earnings today.

Vipin Dixena

23 Jul • 2:54 PM · SEBI-Registered Analyst

Why Is

SUNDARMFIN

in Focus After Radhakishan Damani's Fresh Bet?

Ace investor Radhakishan Damani and his family have acquired a 2.37% stake in

SUNDARMFIN

during the April–June quarter of FY27, after having exited a similar stake in FY26. The investment is valued at around ₹1,160 crore based on current market prices. The move has caught investors' attention because it comes at a time when Sundaram Finance shares have corrected nearly 17% in 2026, suggesting Damani may be taking a contrarian view on the stock. The company remains one of India's leading vehicle finance-focused NBFCs, known for its conservative underwriting, strong asset quality, and consistent return ratios. The entry of a marquee investor is a positive sentiment trigger but should not be the sole investment rationale. Investors should continue to track loan growth, asset quality, net interest margins, credit costs, and return on assets to evaluate whether the recent correction presents a long-term opportunity. Damani's re-entry has brought Sundaram Finance back into focus, but the stock's long-term performance will ultimately depend on its ability to sustain earnings growth and maintain its strong lending franchise—not just on changes in its shareholding pattern

Vimal K

5 Jul • 8:20 AM · SEBI-Registered Analyst

WATCH OUT FOR CORPORATE ACTIONS TODAY

Watch out for the Corporate actions today 06-07-2026 on the below mentioned stocks: - Sundaram Finance Ltd, Pilani Investment and Industries Corporation Ltd, DCM Shriram International Ltd, DJ Mediaprint & Logistics Ltd will tarde Ex-Dividend tomorrow 06-Jul-2026. Ideaforge Technology Ltd, Polyplex Corporation Ltd., Hikal Ltd, Krsnaa Diagnostics Ltd, Astec Lifesciences Ltd are hosting Annual General Meetings (AGM / EGM) tomorrow to vote on critical corporate resolutions.

SUNDARMFIN

PILANIINVS

DCMSHRIRAM

DJML

IDEAFORGE

POLYPLEX

Frequently Asked Questions

Sundaram Multi Pap Ltd. Share Price

Overview

Market Data

Open Price

Prev. Close

Day Low

Day High

52 Week Low

52 Week High

Fundamentals

Quick Bite

Price To Earnings Ratio

Sector PE

PB Ratio

Sector PB

EPS

Dividend Yield

Today's Volume

5 Day Avg. Volume

PEG Ratio

Market Cap.

StockGro Trade views

Technical Analysis

Forecasts 🧭

Financials

Corporate Actions

Mutual Fund Ownership

About Sundaram Multi Pap Ltd. 👋

Expert Opinions

Frequently Asked Questions

What is the share price of Sundaram Multi Pap Ltd.?

What is the market cap of Sundaram Multi Pap Ltd.?

Should I buy Sundaram Multi Pap Ltd. stock now?

What is the 52 week high and low of Sundaram Multi Pap Ltd.?

Is the Sundaram Multi Pap Ltd. stock good to buy?

Is Sundaram Multi Pap Ltd. a good buy for the long term?

Is Sundaram Multi Pap Ltd. overvalued or undervalued?

What is the PE and PB ratio of Sundaram Multi Pap Ltd.?